Relationship between anti-Xa level achieved with prophylactic low-molecular weight heparin and venous thromboembolism in trauma patients: A systematic review and meta-analysis.
Journal
The journal of trauma and acute care surgery
ISSN: 2163-0763
Titre abrégé: J Trauma Acute Care Surg
Pays: United States
ID NLM: 101570622
Informations de publication
Date de publication:
01 08 2022
01 08 2022
Historique:
pubmed:
24
2
2022
medline:
29
7
2022
entrez:
23
2
2022
Statut:
ppublish
Résumé
Trauma patients have simultaneously high venous thromboembolism (VTE) and bleeding risk. Optimal chemoprophylaxis regimens remain unclear. This study aims to answer three questions for trauma patients. Is there any association between anti-Xa and VTE? Does dose adjustment improve prophylactic anti-Xa rates? Does dose adjustment improve anti-Xa adequacy and VTE compared with standard dosing? Systematic search of MEDLINE, Embase, Scopus, and Web of Science occurred in May 2021. Two author reviews included trauma studies that evaluated low molecular weight heparin chemoprophylaxis, reported anti-Xa level, and evaluated more than one outcome. Data were dually extracted and estimated effects were calculated using RevMan 5.4 applying the Mantel-Haenszel method. Analysis 1 compared patients with peak anti-Xa of 0.2 IU/mL or greater or trough 0.1 IU/mL or greater to those with lower anti-Xa using VTE as the primary outcome. Analysis 2 reported the effect of dose adjustment on anti-Xa. Analysis 3 compared standard dosing to dose adjustment with the primary outcome being anti-Xa adequacy; secondary outcomes were VTE, pulmonary embolism, and bleeding complications. There were 3,401 studies evaluated with 24 being included (19 retrospective studies, 5 prospective studies). In analysis 1, achieving adequate anti-Xa was associated with reduced odds of VTE (4.0% to 3.1%; odds ratio [OR], 0.52; p = 0.03). Analysis 2 demonstrated that 768 (75.3%) patients achieved prophylactic anti-Xa with adjustment protocols. Analysis 3 suggested that dose-adjusted chemoprophylaxis achieves prophylactic anti-Xa more frequently (OR, 4.05; p = 0.007) but without VTE (OR, 0.72; p = 0.15) or pulmonary embolism (OR, 0.48; p = 0.10) differences. In subgroup analysis, anti-Xa dose adjustment also suggested no VTE reduction (OR, 0.68; p = 0.08). Patients with higher anti-Xa levels are less likely to experience VTE, and anti-Xa guided chemoprophylaxis increases anti-Xa adequacy. However, dose adjustment, including anti-Xa guided dosing, may not reduce VTE. Systematic Review Meta-Analysis, Level IV.
Sections du résumé
BACKGROUND
Trauma patients have simultaneously high venous thromboembolism (VTE) and bleeding risk. Optimal chemoprophylaxis regimens remain unclear. This study aims to answer three questions for trauma patients. Is there any association between anti-Xa and VTE? Does dose adjustment improve prophylactic anti-Xa rates? Does dose adjustment improve anti-Xa adequacy and VTE compared with standard dosing?
METHODS
Systematic search of MEDLINE, Embase, Scopus, and Web of Science occurred in May 2021. Two author reviews included trauma studies that evaluated low molecular weight heparin chemoprophylaxis, reported anti-Xa level, and evaluated more than one outcome. Data were dually extracted and estimated effects were calculated using RevMan 5.4 applying the Mantel-Haenszel method. Analysis 1 compared patients with peak anti-Xa of 0.2 IU/mL or greater or trough 0.1 IU/mL or greater to those with lower anti-Xa using VTE as the primary outcome. Analysis 2 reported the effect of dose adjustment on anti-Xa. Analysis 3 compared standard dosing to dose adjustment with the primary outcome being anti-Xa adequacy; secondary outcomes were VTE, pulmonary embolism, and bleeding complications.
RESULTS
There were 3,401 studies evaluated with 24 being included (19 retrospective studies, 5 prospective studies). In analysis 1, achieving adequate anti-Xa was associated with reduced odds of VTE (4.0% to 3.1%; odds ratio [OR], 0.52; p = 0.03). Analysis 2 demonstrated that 768 (75.3%) patients achieved prophylactic anti-Xa with adjustment protocols. Analysis 3 suggested that dose-adjusted chemoprophylaxis achieves prophylactic anti-Xa more frequently (OR, 4.05; p = 0.007) but without VTE (OR, 0.72; p = 0.15) or pulmonary embolism (OR, 0.48; p = 0.10) differences. In subgroup analysis, anti-Xa dose adjustment also suggested no VTE reduction (OR, 0.68; p = 0.08).
CONCLUSION
Patients with higher anti-Xa levels are less likely to experience VTE, and anti-Xa guided chemoprophylaxis increases anti-Xa adequacy. However, dose adjustment, including anti-Xa guided dosing, may not reduce VTE.
LEVEL OF EVIDENCE
Systematic Review Meta-Analysis, Level IV.
Identifiants
pubmed: 35195094
doi: 10.1097/TA.0000000000003580
pii: 01586154-202208000-00020
doi:
Substances chimiques
Anticoagulants
0
Enoxaparin
0
Heparin, Low-Molecular-Weight
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e61-e70Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Toker S, Hak DJ, Morgan SJ. Deep vein thrombosis prophylaxis in trauma patients. Thrombosis . 2011;2011(101566937):505373.
Anderson DR, Morgano GP, Bennett C, Dentali F, Francis CW, Garcia DA, Kahn SR, Rahman M, Rajasekhar A, Rogers FB, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv . 2019;3(23):3898–3944.
Ahlquist S, Park HY, Kelley B, Holly L, Shamie AN, Park DY. Venous thromboembolism chemoprophylaxis within 24 hours of surgery for spinal cord injury: is it safe and effective? Neurospine . 2020;17(2):407–416.
Ahmed FS, Khan M, Tang AL, Azim A, Kulvatunyou N, O’Keeffe T, Gries LM, Joseph B. Optimal timing of initiation thromboprophylaxis in spinal trauma after operative intervention: a propensity-matched analysis. J Am Chem Soc . 2017;225(4 Suppl1):S58.
Bensink J, Hamblin S, Jaynes M, Guillamondegui O. Implementation of an early VTE prophylaxis protocol following surgery for traumatic spinal injury. Crit Care Med . 2018;46(Suppl 1):781.
Chang R, Scerbo MH, Schmitt KM, Adams SD, Choi TJ, Wade CE, Holcomb JB. Early chemoprophylaxis is associated with decreased venous thromboembolism risk without concomitant increase in intraspinal hematoma expansion after traumatic spinal cord injury. J Trauma Acute Care Surg . 2017;83(6):1088–1094.
DiGiorgio AM, Tsolinas R, Alazzeh M, Haefeli J, Talbott JF, Ferguson AR, Bresnahan JC, Beattie MS, Manley GT, Whetstone WD, et al. Safety and effectiveness of early chemical deep venous thrombosis prophylaxis after spinal cord injury: pilot prospective data. Neurosurg Focus . 2017;43(5):E21.
Hamidi MK, Hanna K, Gries LM, Zeeshan M, Haddadin Z, O’Keeffe T, Ditillo M, Northcutt A, Tang AL, Joseph B. Early initiation of Thromboprophylaxis in operative spine trauma does not increase the risk of bleeding complication. J Am Chem Soc . 2019;229(4 Suppl 1):S194.
Benjamin E, Aiolfi A, Recinos G, Inaba K, Demetriades D. Timing of venous thromboprophylaxis in isolated severe pelvic fracture: effect on mortality and outcomes. Injury . 2019;50(3):697–702.
Jehan F, O’Keeffe T, Khan M, Chi A, Tang A, Kulvatunyou N, Gries L, Joseph B. Early thromboprophylaxis with low-molecular-weight heparin is safe in patients with pelvic fracture managed nonoperatively. J Surg Res . 2017;219:360–365.
Alvi MA, Lu V. Early versus late pharmacologic thromboprophylaxis in traumatic intracranial hemorrhage: a systematic review and meta-analysis. J Neurosurg . 2019;131(1):50–51.
Benjamin E, Recinos G, Aiolfi A, Inaba K, Demetriades D. Pharmacological thromboembolic prophylaxis in traumatic brain injuries: low molecular weight heparin is superior to unfractionated heparin. Ann Surg . 2017;266(3):463–469.
Brandi G, Schmidlin A, Klinzing S, Schupbach R, Unseld S, Pagnamenta A. Delayed prophylaxis with unfractionated heparin increases the risk of venous thromboembolic events in patients with moderate to severe traumatic brain injury: a retrospective analysis. Anaesth Intensive Ther . 2020;52(1):28–33.
Byrne JP, Mason SA, Gomez D, Hoeft C, Subacius H, Xiong W, Neal M, Pirouzmand F, Nathens AB. Timing of pharmacologic venous thromboembolism prophylaxis in severe traumatic brain injury: a propensity-matched cohort study. J Am Coll Surg . 2016;223(4):621–31.e5.
Phelan HA, Wolf SE, Norwood SH, Aldy K, Brakenridge SC, Eastman AL, Madden CJ, Nakonezny PA, Yang L, Chason DP, et al. A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: the delayed versus early enoxaparin prophylaxis I (DEEP I) study. J Trauma Acute Care Surg . 2012;73(6):1434–1441.
Eberle BM, Schnuriger B, Inaba K, Cestero R, Kobayashi L, Barmparas G, Oliver M, Demetriades D. Thromboembolic prophylaxis with low-molecular-weight heparin in patients with blunt solid abdominal organ injuries undergoing nonoperative management: current practice and outcomes. J Trauma . 2011;70(1):141–147.
Ferguson C, Lewin J. BET 2: Is early chemical thromboprophylaxis safe in patients with blunt trauma solid organ injury (SOI) undergoing non-operative management (NOM)? Emerg Med J . 2018;35(2):127–129.
Adams RC, Hamrick M, Berenguer C, Senkowski C, Ochsner MG. Four years of an aggressive prophylaxis and screening protocol for venous thromboembolism in a large trauma population. J Trauma . 2008;65(2):300–308.
Azarbal A, Rowell S, Lewis J, Urankar R, Moseley S, Landry G, Moneta G. Duplex ultrasound screening detects high rates of deep vein thromboses in critically ill trauma patients. J Vasc Surg . 2011;54(3):743–748.
Hamada SR, Espina C, Guedj T, Buaron R, Harrois A, Figueiredo S, Duranteau J. High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol. Ann Intensive Care . 2017;7(1):97.
Wei MY, Ward SM. The anti-factor Xa range for low molecular weight heparin thromboprophylaxis. Hematol Rep . 2015;7(4):5844.
Pannucci CJ, Fleming KI, Varghese TK Jr., Stringham J, Huang LC, Pickron TB, Prazak AM, Bertolaccini C, Momeni A. Low anti-Factor Xa level predicts 90-day symptomatic venous thromboembolism in surgical patients receiving enoxaparin prophylaxis: a pooled analysis of eight clinical trials. Ann Surg . 2020;9000; Publish Ahead of Print.
Droege M, Droege C, Webb M, Philpott C, Ernst N, Athota K, Wakefield D, Dowd J, Gomaa D, Robinson B, et al. Antithrombin III and anti-XA impact on enoxaparin chemoprophylaxis in highrisk trauma patients. Crit Care Med . 2019;47(1 Suppl 1).
Karcutskie CA, Dharmaraja A, Patel J, Eidelson SA, Padiadpu AB, Martin AG, Lama G, Lineen EB, Namias N, Schulman CI, et al. Association of anti-factor Xa-guided dosing of enoxaparin with venous thromboembolism after trauma. JAMA Surg . 2018;153(2):144–149.
Ko A, Harada MY, Barmparas G, Chung K, Mason R, Yim DA, Dhillon N, Margulies DR, Gewertz BL, Ley EJ. Association between enoxaparin dosage adjusted by anti-factor Xa trough level and clinically evident venous thromboembolism after trauma. JAMA Surg . 2016;151(11):1006–1013.
Robinson S, Zincuk A, Larsen UL, Ekstrøm C, Nybo M, Rasmussen B, Toft P. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial. Crit Care . 2013;17(2):R75.
Vahtera A, Valkonen M, Huhtala H, Pettila V, Kuitunen A. Plasma anti-FXa concentration after continuous intravenous infusion and subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill patients. A randomized clinical trial. Thromb Res . 2017;158:71–75.
Rodier SG, Kim M, Moore S, Frangos SG, Tandon M, Klein MJ, Berry CD, Huang PP, DiMaggio CJ, Bukur M. Early anti-Xa assay-guided low molecular weight heparin chemoprophylaxis is safe in adult patients with acute traumatic brain injury. Am Surg . 2020;86(4):369–376.
Rakhra S, Martin E-L, Fitzgerald M, Udy A. The ATLANTIC study: anti-Xa level assessment in trauma intensive care. Injury . 2020;51(1):10–14.
Scrimenti A, Seabury RW, Miller CD, Ruangvoravat L, Darko W, Probst LA, Cwikla GM. Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit. Pharm Pract-Granada . 2019;17(4):1541.
Kopelman TR, Walters JW, Bogert JN, Basharat U, Pieri PG, Davis KM, Quan AN, Vail SJ, Pressman MA. Goal directed enoxaparin dosing provides superior chemoprophylaxis against deep vein thrombosis. Injury . 2017;48(5):1088–1092.
Droege M, Philpott C, Deichstetter K, Strahm K, Hausfeld K, Robisch A, Boesken TA, Mueller E. Pharmacist-led transitions of care coordination for extended chemoprophylaxis at a Level-1 trauma center. JACCP . 2020;3(8):1663–1664.
Bickford A, Majercik S, Bledsoe J, Smith K, Johnston R, Dickerson J, White T. Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient. Am J Surg . 2013;206(6):847–842.
Rodier SG, Bukur M, Moore S, Frangos SG, Tandon M, DiMaggio CJ, Ayoung-Chee P, Marshall GT. Weight-based enoxaparin with anti-factor Xa assay-based dose adjustment for venous thromboembolic event prophylaxis in adult trauma patients results in improved prophylactic range targeting. Eur J Trauma Emerg Surg . 2021;47(1):145–151.
Stutsrim AE, Eady JM, Collum M, Rebo GJ, Rebo KA, Miller PR, Nunn AM. Weight-based enoxaparin achieves adequate anti-Xa levels more often in trauma patients: a prospective study. Am Surg . 2021;87(1):77–82.
Ley EJ, Brown CVR, Moore EE, Sava JA, Peck K, Ciesla DJ, Sperry JL, Rizzo AG, Rosen NG, Brasel KJ, et al. Updated guidelines to reduce venous thromboembolism in trauma patients: a Western Trauma Association critical decisions algorithm. J Trauma Acute Care Surg . 2020;89(5):971–981.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA . 2000;283(15):2008–2012.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med . 2009;6(7):e1000097.
Veritas Health Innovation. Covidence systematic review software . Melbourne, Australia; 2021. Available from: www.covidence.org .
Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of Google scholar in evidence reviews and its applicability to Grey literature searching. PLoS One . 2015;10(9):e0138237.
Roger FB. Venous thromboembolism in trauma patients: a review. Surgery . 2001;130(1):1–12.
National Heart Lung and Blood Institute. Venous Thromboembolism 2021 [cited 2021 October 10, 2021]. Available at: https://www.nhlbi.nih.gov/health-topics/venous-thromboembolism . Accessed October 10, 2021.
Dhillon NK, Hashim YM, Berezin N, Yong F, Conde G, Mason R, Ley EJ. Characterizing the delays in adequate thromboprophylaxis after TBI. Trauma Surg Acute Care Open . 2021;6(1):e000686.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol . 2014;14(1):135.
The Nordic Cochrane Centre. Review Manager (RevMan) . The Cochrane Collaboration; 2021.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) . 2003;327(7414):557–560.
Malinoski D, Jafari F, Ewing T. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rate in critically ill trauma and surgical patients. J Vasc Surg . 2011;53(2):548.
Bethea A, Samanta D. Risk factors for nontherapeutic anti-XA assays in trauma patients with enoxaparin VTE prophylaxis. Crit Care Med . 2019;47(1 Suppl 1).
Vincent PD, Albert M, Champagne MC, Zikos T, Boulanger I, Blais L, Williamson DR. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. J Crit Care . 2011;26(4):347–351.
Droege ME, Mueller EW, Besl KM, Lemmink JA, Kramer EA, Athota KP, Droege CA, Ernst NE, Keegan SP, Lutomski DM, et al. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg . 2014;76(2):450–456.
Imran JB, Madni TD, Clark AT, Rizk P, Huang E, Minshall CT, Taveras LR, Cunningham HB, Eastman AL, Koshy JP, et al. Inability to predict subprophylactic anti-factor Xa levels in trauma patients receiving early low-molecular-weight heparin. J Trauma Acute Care Surg . 2018;85(5):867–872.
Farrar JE, Droege ME, Philpott CD, Mueller EW, Ernst NE, Makley AT, Deichstetter KM, Droege CA. Impact of weight on anti-Xa attainment in high-risk trauma patients on enoxaparin chemoprophylaxis. J Surg Res . 2021;264:425–434.
Jacobs BN, Cain-Nielsen AH, Jakubus JL, Mikhail JN, Fath JJ, Regenbogen SE, Hemmila MR. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma. J Trauma Acute Care Surg . 2017;83(1):151–158.
Rappold JF, Sheppard FR, Carmichael Ii SP, Cuschieri J, Ley E, Rangel E, Seshadri AJ, Michetti CP. Venous thromboembolism prophylaxis in the trauma intensive care unit: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. Trauma Surg Acute Care Open . 2021;6(1):e000643.
Kay AB, Majercik S, Sorensen J, Woller SC, Stevens SM, White TW, Morris DS, Baldwin M, Bledsoe JR. Weight-based enoxaparin dosing and deep vein thrombosis in hospitalized trauma patients: a double-blind, randomized, pilot study. Surgery . 2018;S0039-6060(18):30094–30091.
Berendtson AE, Costantini TW, Lane J, Box K, Coimbra R. If some is good, more is better: an enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis. J Trauma Acute Care Surg . 2016;81(6):1095–1100.
Bethea A, Adams E, Lucente FC, Samanta D, Chumbe JT. Improving pharmacologic prevention of VTE in Trauma: IMPACT-IT QI Project. Am Surg . 2018;84:1097–104.
Bigos R, Solomon E, Dorfman JD, Ha M. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients. J Surg Res . 2021;265:122–30.
Nunez JM, Becher RD, Rebo GJ, Farrah JP, Borgerding EM, Stirparo JJ, Lauer C, Kilgo P, Miller PR. Prospective evaluation of weight-based prophylactic enoxaparin dosing in critically ill trauma patients: adequacy of antiXa levels is improved. Am Surg . 2015;81(6):605–609.